Ulcerative colitis (UC) specifically affects the colon and rectum through multifactorial
mechanisms associated with genetic alterations, environmental factors, microbiota, and …

The cumulative impact of chronic inflammation in patients with inflammatory bowel diseases
predisposes to the development of inflammatory bowel disease-associated colorectal …

Intestinal immune cell trafficking has been identified as a central event in the pathogenesis
of inflammatory bowel diseases (IBD). Intensive research on different aspects of the immune …

In 2018, the pan-Janus kinase (JAK) inhibitor tofacitinib was launched for the treatment of
ulcerative colitis (UC). Although tofacitinib has proven efficacious in patients with active UC …

Inflammatory bowel diseases (IBD), encompassing ulcerative colitis (UC), and Crohn's
disease (CD), are a group of disorders characterized by chronic, relapsing, and remitting, or …

Abstract Foxp3+ T regulatory (Treg) cells suppress inflammation and are essential for
maintaining tissue homeostasis. A growing appreciation of tissue‐specific Treg functions …

Chronic inflammation caused by infiltrating immune cells can promote colitis‐associated
dysplasia/colitic cancer in ulcerative colitis (UC) by activating inflammatory cytokine …

Targeting leukocyte trafficking in the management of inflammatory bowel disease [IBD] has
been a significant therapeutic advance over the past 15 years. However, as with other …

Inflammatory bowel disease (IBD) is a chronic disease that requires lifelong medication and
whose incidence is increasing over the world. There is currently no cure for IBD, and the …

Ulcerative colitis (UC) is driven by immune and stromal subsets, culminating in epithelial
injury. Vedolizumab (VDZ) is an anti-integrin antibody that is effective for treating UC. VDZ is …